INTERVENTION TO REDUCE HBV, HCV AND HIV IN IDUS

描述：(申请人摘要) 到目前为止，还没有进行过关于更换注射器的随机对照试验 地点。这项研究既是有效性研究，也是可行性研究。 一项两组随机临床试验的设计 注射吸毒者被分配到：(A)能够使用注射器 交换，或(B)无法获得注射器交换，并且 鼓励使用合法的药房销售代替。所有受试者都被跟踪 每六个月一次，信息是通过风险行为收集的 评估，关于针头使用和使用的补充问卷 采购，定位信息，安非他明和可卡因的尿液检测 代谢物、吗啡和肝炎标志物的血清学检测 B病毒。还将监测人类免疫缺陷病毒的标志物。 将有一个数据安全和监测委员会，负责监督 研究进展，并将对伦理问题进行监督 参与了这项研究。

DESCRIPTION: (Applicant's Abstract) To date no randomized controlled trials of syringe exchange have taken place. This research is both an efficacy study and a feasibility study design of a two group randomized clinical trial in which current and former injection drug users are assigned to: (a) being able to use a syringe exchange, or (b) not having access to the syringe exchange and being encouraged to use legal pharmacy sales instead. All subjects are followed up every six months and information is collected with Risk Behavior Assessment, a supplementary questionnaire concerning needle use and procurement, locator information, urine testing for amphetamines, cocaine metabolites, and morphine, and serological testing for markers of Hepatitis B Virus. Markers of Human Immunodeficiency Virus will also be monitored. There will be a Data Safety and Monitoring Board who will be overseeing the progress of the research and will have oversight over the ethical issues involved in this research.